AIM ImmunoTech Inc.

today announced that Thomas Equels, Chief Executive Officer, will be participating in two upcoming investor conferences: https://bit.ly/3rKYAOB

Inc. today announced that it has finalized the protocol for a planned Phase 2 study of the company’s drug as a therapy for locally advanced or metastatic late-stage . https://bit.ly/3l7i5gg

announced that AIM and have a signed Clinical Trial Agreement ( ) for a Phase 2a Human Challenge Trial ( ) to test the company’s drug as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and A virus (H3N2): https://bit.ly/2XZQdSf

New York Times - "This is really scary:" Kid Struggle with Long COVID

‘This Is Really Scary’: Kids Struggle With Long Covid Lingering physical, mental and neurological symptoms are affecting children as well as adults, including many who had mild reactions to the initial coronavirus infection.